Article | Open

Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients

  • Scientific Reports 7, Article number: 11102 (2017)
  • doi:10.1038/s41598-017-10734-y
  • Download Citation
Received:
Accepted:
Published online:

Abstract

Reduced biodiversity and increased representation of opportunistic pathogens are typical features of gut microbiota composition in aging. Few studies have investigated their correlation with polypharmacy, multimorbidity and frailty. To assess it, we analyzed the fecal microbiota from 76 inpatients, aged 83 ± 8. Microbiome biodiversity (Chao1 index) and relative abundance of individual bacterial taxa were determined by next-generation 16S rRNA microbial profiling. Their correlation with number of drugs, and indexes of multimorbidity and frailty were verified using multivariate linear regression models. The impact of gut microbiota biodiversity on mortality, rehospitalizations and incident sepsis was also assessed after a 2-year follow-up, using Cox regression analysis. We found a significant negative correlation between the number of drugs and Chao1 Index at multivariate analysis. The number of drugs was associated with the average relative abundance of 15 taxa. The drug classes exhibiting the strongest association with single taxa abundance were proton pump inhibitors, antidepressants and antipsychotics. Conversely, frailty and multimorbidity were not significantly associated with gut microbiota biodiversity. Very low Chao1 index was also a significant predictor of mortality, but not of rehospitalizations and sepsis, at follow-up. In aging, polypharmacy may thus represent a determinant of gut microbiota composition, with detrimental clinical consequences.

Introduction

Human gut microbiota composition, which is relatively stable during the adult lifespan, faces significant alterations with aging1, 2. Most studies have emphasized the age-related reduction in biodiversity3,4,5, which is more pronounced in centenarians6, 7 and in subjects living in nursing homes3, 8.

For example, in a cohort of 178 Irish older individuals, institutionalization was associated with a reduced representation of short-chain fatty acids (SCFA) producers and expansion of taxa including Parabacteroides, Eubacterium, Coprococcus and Anaerotruncus in gut microbiota3. These alterations may partly depend on different dietary patterns followed by elderly living in nursing homes, given the strong influence of diet on gut microbiota composition9. However, recent studies have demonstrated that most of these alterations are independent of nutrient intake8. These specific patterns, in the absence of acute diseases, remain relatively stable over time10.

Gut microbiota composition in the elderly may have important physio-pathological implications, since in aged murine models the gut dysbiosis promotes chronic inflammation and is associated with a reduced innate immunity function11. Moreover, depletion of taxa producing SCFA may promote anabolic resistance12.

To date, very few studies have investigated the possible association of human gut microbiota composition with clinical and functional parameters in aging. In a subgroup of participants to the Eldermet Study, Jeffery and colleagues identified a group of microbial taxa, including Anaerotruncus, Desulfovibrio and Coprobacillus, whose relative abundance in the gut was inversely correlated with Barthel Index8. Similarly, in a cohort of 364 couples of elderly female twins, Jackson et al. identified 21 gut microbial taxa whose relative abundance was significantly associated with the Rockwood Frailty Index13. These findings allow to hypothesize that frailty is associated to a specific microbiota composition.

However, the association of gut microbiota composition with multimorbidity and polypharmacy has not been investigated yet, even if the current literature state of art supports the hypothesis that gut dysbiosis influences the pattern of aging and pathophysiology of some diseases14. This is especially true in the hospital setting, where dysbiosis is frequently detected in older patients15.

In the present study, we analyzed the fecal microbiota composition of 76 elderly patients without gastrointestinal diseases hospitalized in a large Italian geriatric ward. The aim was to assess the possible association of gut microbiota composition, determined through metagenomics analysis (16S rRNA microbial profiling), with the domains of frailty, multimorbidity and polypharmacy, and to elucidate the consequences of a reduced biodiversity on clinical outcomes.

Methods

Study design and population

With an observational study design, we enrolled 76 elderly (age ≥ 65) multimorbid (≥2 chronic diseases) patients who were acutely hospitalized to the Internal Medicine ward of Parma University Hospital Geriatric-Rehabilitation Department, in Northern Italy, from November 2014 to April 2015. Enrolled patients were all urgently admitted from the Emergency Department and suffered from acute extra-intestinal diseases and a high burden of multimorbidity, in line with the case-mix of the ward16.

Excluded from the study were subjects with acute or chronic digestive diseases, including inflammatory bowel disease, intestinal ischemia, diverticulitis, cirrhosis, acute or chronic pancreatitis, cholecystitis, intestinal cancer, or with previous abdominal surgery, and subjects who were treated with antibiotics for more than 3 days. Similarly, subjects with expected survival < 30 days or undergoing artificial nutrition were also excluded. In fact, all these conditions have an established association with gut dysbiosis17. Conversely, subjects exposed to antibiotic treatment for less than 3 days at the time of enrolment were included in the study, since in older hospitalized patients15 and in other settings10 short-term antibiotic therapy was not associated with significant alterations in overall microbiota composition.

Moreover, another group of 25 healthy active elderly volunteers (age ≥ 65), without multimorbidity (no more than one chronic illness) and frailty and not taking polypharmacy (<5 drugs), was enrolled in the study on an outpatient basis as control group. None of the volunteers had diseases known to influence fecal microbiota composition or underwent systemic antibiotic treatment in the month before the evaluation.

The protocol followed the principles of the Declaration of Helsinki, and all participants gave their informed consent. The Ethics Committee of the University of Parma approved the study (ID 14091).

Data collection and laboratory analyses

Hospitalized patients were enrolled within 72 hours from hospital admission. Data about main diagnosis, comorbidities, number and type of medications, functional performance and weight were collected for each patient. The multimorbidity burden was assessed through the Cumulative Illness Rating Scale (CIRS) model, and the CIRS Comorbidity Score was calculated18. This score, ranging from 0 to 56, is the sum of the individual indexes of disease severity, ranging from 0 (absence of disease) to 4 (life-threatening condition), assigned to 14 items representing possible organs affected by an acute or chronic disease. The functional performance of participants was assessed according to the Rockwood Clinical Frailty Scale (RCFS)19. Polypharmacy was assessed through a systematic recognition of drugs chronically taken by every patient.

Within the first 72 hours of hospital stay, each patient provided a stool sample of at least 2 grams by spontaneous evacuation. All patients followed the same hospital-based oral diet at the time of stool sample collection, characterized by balanced intake of energy (1700 Kcal/day) and macronutrients. Fecal samples were immediately frozen at −20 °C and delivered to the Laboratory of Probiogenomics of Parma University for processing and 16S rRNA microbial profiling analyses.

Control subjects underwent a general clinical examination, to assess eligibility for inclusion in the study. Each of them provided a stool sample, which was handled in the same way as samples of hospitalized subjects.

The laboratory procedures and bioinformatics analyses were performed according to a validated protocol15, 20, which is fully described elsewhere20 and summarized in the Supplemental Material. The bacterial 16S rRNA reads were analyzed with the QIIME software21 and pooled in Operational Taxonomic Units (OTUs) with the uclust software22. The OTU data were used to calculate the index of biodiversity Chao1 and to perform a beta diversity analysis with the Principal Coordinate Analysis (PCoA) method based on unweighted UniFrax. Taxonomic classification of OTUs was made using the QIIME software suite21 and the related 16S database SILVA23, and the relative abundance of every taxon was determined in all samples.

Evaluation of clinical outcomes

In order to prospectively verify the clinical effect of a reduced fecal microbiota biodiversity, hospitalized patients were actively followed-up, as part of the normal clinical procedures adopted in our institution. Thus, data about mortality and rehospitalizations were collected for two years after discharge. Namely, the dates of death or hospital readmission were considered. In case of hospital readmission, the presence of sepsis was also investigated as outcome. In fact, epidemiological studies have demonstrated an association between gut dysbiosis and risk of sepsis24.

Statistical analyses

Clinical data and alpha-diversity indexes were expressed as average ± standard deviation or, for non-normally skewed distributions, median and tertiles or quartiles. The relative abundance of single taxa within the gut microbiota of every patient was expressed as percentage on the whole number of bacteria detected by metagenomics analyses.

The overall fecal microbiota composition, in terms of inter-individual variability, was compared between hospitalized patients and healthy controls using Permanova and Kendall tau-rank co-occurrence analysis.

In hospitalized patients, Pearson correlation analysis was carried out to test the association between each of the clinical (CIRS Comorbidity Score, RCFS, number of drugs) and microbial biodiversity variables (Chao1 index, relative abundance of single taxa). In multivariate linear regression models, age, sex, exposure to antibiotics and number of days under antibiotic treatment were considered as potential confounders. The average Chao1 index was also compared between the top and the bottom tertile of CIRS Comorbidity Score, RCFS and number of drugs using a one-way Kruskal-Wallis analysis of variance adjusted for age, sex and antibiotic exposure. Finally, an explorative analysis with multivariate linear regression was carried out to test the possible association between the relative abundance of taxa significantly related to polypharmacy and exposure to specific drug classes, i.e. diuretics, proton-pump inhibitors (PPIs), neuroleptics, antidepressants, acetaminophen, antinflammatory drugs, antihypertensive and lipid-lowering treatments.

Finally, in hospitalized patients, univariate and multivariate models of Cox regression analysis were built to assess the association between fecal microbiota biodiversity, measured with the Chao1 index, and clinical outcomes, i.e. two-year mortality, rehospitalization, and incident sepsis. Kaplan-Meier survival analysis was also performed after categorization of patients in tertiles of Chao1 index.

Statistical analyses were carried out using QSPSS and the SAS statistical package, version 9.1 (SAS Institute Inc., Cary, North Carolina), considering p values ≤ 0.05 as significant.

Data availability statement

The 16S rRNA profiling data sequenced in this study, together with essential clinical data, were deposited in SRA database under the following accession numbers: PRJNA297268 and PRJNA297269.

Results

Clinical features of hospitalized patients

The 76 hospitalized patients (39 M, 37 F) enrolled in this study were 83 ± 8 years old and displayed a high burden of chronic multimorbidity (CIRS Comorbidity Score median 11, first tertile ≤ 7, second tertile 8–14, third tertile ≥ 15), frailty (RCFS median 5, first tertile ≤ 4, second tertile 5–6, third tertile ≥ 7) and polypharmacy (number of drugs median 10, first tertile ≤ 7, second tertile 8–10, third tertile ≥ 11 drugs). Forty patients out of 76 (52.6%) were taking antibiotic treatment at the time of stool sample collection, but in no cases this treatment had been lasting for more than 72 hours. The most prevalent chronic comorbidities are listed in Table 1. The most frequent reasons for hospital admission were pneumonia, COPD with respiratory failure, congestive heart failure, arrhythmic syncope, fall-related trauma, ischemic stroke.

Table 1: Clinical metadata. Main characteristics of hospitalized patients enrolled in the study (n = 76).

According to the Rockwood model, the prevalence of frailty-disability (RCFS 5–9), pre-frailty (RCFS 4) and fitness (RCFS 1–3) were 57%, 22% and 21%, respectively. The prevalence of polypharmacy (≥5 drugs chronically taken before hospitalization) was 94%. The most frequent drug classes were PPIs (73%), antihypertensives (63%) and diuretics (60%).

The main clinical features of hospitalized participants are summarized in Table 1.

Comparison of fecal microbiota composition between hospitalized patients and controls

Hospitalized patients exhibited a significantly different fecal microbiota composition, in terms of beta-diversity, than controls enrolled on an outpatient basis (Permanova p = 0.001). The Principal Coordinate Analysis (PCoA) based on unweighed UniFrac showed two distinct microbiome clusters, corresponding to hospitalized patients and older controls (Fig. 1).

Figure 1
Figure 1

Gut microbiota in cases and controls. Comparison of the overall fecal microbiota composition, represented with 3D Principal Coordinate Analysis scatterplot, between 76 older hospitalized patients with a high burden of multimorbidity, frailty and polypharmacy, and 25 older healthy-active volunteers without polypharmacy.

Gut microbiota biodiversity and clinical domains in hospitalized subjects

The 16S rRNA microbial profiling analysis of the 76 stool samples, collected while patients followed the same hospital-based diet, produced a total of 3470225 filtered reads, with an average of 45661 per sample, corresponding to an average number of 888 OTUs. The average alpha-diversity curve, determined through the Chao1 index, is depicted in Fig. 2.

Figure 2
Figure 2

Average gut microbiota biodiversity of hospitalized patients. Average gut microbiota alpha-diversity curve of the 76 stool samples analyzed by 16S rRNA microbial profiling metagenomics techniques. The curve represents the average Chao1 index, corresponding to the number of Operational Taxonomic Units (OTUs), at increasing sequencing depth.

At a univariate Pearson analysis, the Chao1 index was significantly and negatively correlated with the number of drugs (r = −0.278, p = 0.018), but not with the CIRS Comorbidity Score (r = 0.015, p = 0.899) and RCFS (r = −0.073, p = 0.570). At a multivariate linear regression model, using backward selection, accounting for age, sex, CIRS Comorbidity Score, RCFS and days of exposure to antibiotic treatment, the negative correlation between number of drugs and Chao1 index persisted as statistically significant (β ± SE −28.54 ± 9.88, p = 0.005) (Table 2).

Table 2: Association of gut microbiota biodiversity with clinical domains in hospitalized patients. Multivariate linear regression model, obtained by backward selection analysis of covariates, testing the possible correlation of Chao1 index of alpha-diversity (biodiversity) in gut microbiota with clinical domains in 76 elderly patients hospitalized for acute extra-intestinal diseases.

As shown in Fig. 3a, comparison of the alpha diversity Chao1 curves between those patients in the top tertile of number of drugs (i.e., chronically taking ≥ 11 drugs) and patients in the bottom tertile (i.e., chronically taking ≤7 drugs) revealed a statistically significant difference (p for trend = 0.03 at different sequencing depths). This difference persisted even after correction for age, sex, CIRS Comorbidity Score and RCFS (p for trend = 0.04 at different sequencing depths). Conversely, similar analyses carried out comparing patients in the top vs the bottom tertile of CIRS Comorbidity Score (≥15 vs ≤7) (Fig. 3b) and patients in the top vs the bottom tertile of RCFS (≥7 vs ≤ 4) (Fig. 3c) did not show any statistical difference (p = 0.969 and p = 0.300, respectively).

Figure 3
Figure 3

Gut microbiota biodiversity and polypharmacy, multimorbidity and frailty. Comparison of the average gut microbiota alpha-diversity curves, representing Chao1 indexes of biodiversity as function of sequencing depth, between the top and the bottom tertile of 76 patients categorized for (a) number of drugs, (b) Cumulative Illness Rating Scale (CIRS) Comorbidity Score, and (c) Rockwood Clinical Frailty Scale.

Gut microbiota inter-individual variability and clinical domains in hospitalized patients

Beta-diversity analysis of inter-individual variability, performed with the PCoA method based on an unweighted UniFrax matrix, showed no identifiable microbiota clusters, even after categorization of stool samples for tertiles of number of drugs, CIRS Comorbidity Score, and RCFS (Fig. 4). PCA scatter plots obtained categorizing patients according to chronic exposure to specific drug treatments are shown in Supplemental Material. No significant clusters could be identified as well.

Figure 4
Figure 4

Inter-individual variability of gut microbiota in hospitalized patients and clinical domains. Beta-diversity analysis of inter-individual variability within the 76 stool samples of hospitalized patients, performed with the PCoA method based on an unweighted UniFrax matrix. (a) All samples; (b) samples categorized for Cumulative Illness Rating Scale (CIRS) comorbidity score tertiles; (c) samples categorized for Rockwood Clinical Frailty Scale tertiles; (d) samples categorized for number of drugs tertiles.

Association of single taxa with clinical domains in hospitalized patients

The overall composition of gut microbiota at genus level for each sample analyzed is depicted in Supplemental Fig. 1. The possible association of the relative abundance of each detected microbial taxon with the considered clinical variables (number of drugs, RCFS, CIRS Comorbidity Score) was tested in Pearson correlation models, whose results are shown in Supplemental Material. For each taxon, multivariate models were then built, considering also the length of antibiotic exposure as potential confounder.

In these multivariate models, the relative abundance of fifteen taxa was significantly associated (p ≤ 0.05) with the number of drugs (Table 3). The association was negative for four taxa, including Massilia and unclassified member of Lachnospiraceae family, and positive for eleven taxa, including Bradyrhizobium, Coprobacter, Helicobacter and Prevotella.

Table 3: Association of the relative abundance of single gut bacteria with clinical domains in hospitalized patients. Significant correlations between relative abundance of specific taxa of gut microbiota, identified by 16S rRNA microbial profiling analyses, and clinical parameters (number of drugs, Rockwood Clinical Frailty Scale and CIRS Comorbidity Score) at multivariate linear regression models. Taxa identified in the gut microbiota but lacking any significant correlation with the considered clinical parameters are not shown, but are fully listed in Supplemental Material.

Moreover, the relative abundance of seven taxa was significantly and positively associated (p ≤ 0.05) with RCFS (Table 2), and the relative abundance of ten taxa was significantly associated (p ≤ 0.05) with CIRS Comorbidity Score (Table 2).

Association of single taxa with specific drugs in hospitalized patients

For the fifteen taxa whose relative abundance in gut microbiota was significantly associated with the number of drugs, we tested whether the relative abundance was associated to exposure to specific drug classes. The significant results of multivariate models, considering age, sex, RCFS, number of drugs, CIRS Comorbidity Score, days of antibiotic treatment and exposure to specific drug classes, i.e., diuretics, proton-pump inhibitors (PPIs), neuroleptics, antidepressants, acetaminophen, antinflammatory drugs, antihypertensive and lipid-lowering drugs, as potential confounders, are shown in Table 4.

Table 4: Association of the relative abundance of single gut bacteria with specific drug classes in hospitalized patients. Significant correlations between relative abundance of specific taxa of gut microbiota, identified by 16S rRNA microbial profiling analyses, and exposure to specific drugs classes at multivariate linear regression models. Taxa whose relative abundance was not significantly correlated with any specific drug treatment considered in the analysis (diuretics, proton-pump inhibitors, neuroleptics, antidepressants, acetaminophen, antinflammatory drugs, antihypertensive and lipid-lowering drugs) are not shown.

Fecal microbiota biodiversity and clinical outcomes in hospitalized patients

After a two-year follow-up period, 48 patients (63%) had died, 43 had been rehospitalized (56%), and 18 had had at least one incident episode of sepsis (24%). At univariate and multivariate models of Cox regression analysis, Chao1 index of fecal microbiota biodiversity < 1105, corresponding to the 66th percentile, was a significant predictor of death (RR 2.56, 95% CI 1.21–5.96, p = 0.012 adjusted for age, sex, CIRS Comorbidity Score, RCFS and number of drugs), but not of rehospitalization (RR 1.00, 95% CI 0.99–1.03, age- and sex-adjusted p = 0.43) or sepsis (RR 0.99, 95% CI 0.99–1.02, age- and sex-adjusted p = 0.29).

Kaplan-Meier analysis, depicted in Fig. 5, confirmed that fecal microbiota dysbiosis, with Chao1 index < 1105, was associated with a significantly reduced survival (log-rank 2.1725, p = 0.045).

Figure 5
Figure 5

Fecal microbiota biodiversity and survival in hospitalized patients. Survival distribution function of 76 hospitalized patients categorized according to values of Chao1 Index of biodiversity in fecal microbiota. Subjects with higher biodiversity (upper tertile of Chao1 Index, values ≥ 1105) have a statistically longer survival than patients with deeper dysbiosis after a 2-year follow-up.

Discussion

In this study, we have demonstrated that, in a group of older hospitalized patients, polypharmacy was significantly associated with gut microbiota dysbiosis, i.e. reduction in species richness and significant variations in the average relative abundance of a large number of taxa, including Helicobacter. Dysbiosis also exhibited a significant association with mortality at follow-up. Healthy-active older subjects without polypharmacy did not instead exhibit dysbiosis.

Among specific drug classes, PPIs, antipsychotics and antidepressants had the strongest associations with gut microbiota composition. Conversely, indexes of multimorbidity and frailty/disability were not significantly associated with dysbiosis, albeit the average relative abundance of some taxa, including the well-known Prevotella and Enterobacter, was significantly associated with these indexes.

These results represent the first demonstration to date of the association between polypharmacy and gut microbiota composition, at both quantitative and qualitative level, in a group of elderly hospitalized patients following the same dietary regimen. Thus, this could be an important basis for designing future research aimed at exploring the possible interconnections between gut microbiota composition and (un)successful aging, and for better understanding the pathophysiology of multiple drug treatments.

However, some study limitations should be considered. First, the studied population had a high burden of chronic diseases and disability, whose impact on gut microbiota composition may not be completely measured and explained by the considered indexes. For the same reason, the sample size could have been insufficient to fully represent the high inter-individual variability of microbiota, and could have influenced the results. Second, the studied population had different admission diagnoses. The association of some of these acute diseases, such as pneumonia, congestive heart failure, and stroke, with gut microbiota has been hypothesized25, but not verified in population-based studies26. Even if subjects with diseases known to have an established association with dysbiosis, such as IBD, were excluded from the study, and no significant microbiome clusters were identified among subjects with the same acute disease, the population heterogeneity may have represented a possible source of bias. Third, other factors explaining gut microbiota variability in adults, such as long-term dietary habits and smoking26, were not considered in the present study. For all these reasons, our results should be considered as hypothesis generator for future research rather than definitive remarks on the topic. Future research should also verify whether fecal microbiota composition changes with medication revision in older patients.

The concept that gut microbiota composition may be influenced by drug therapy and drug-drug interactions has already been proposed by some authors26,27,28. However, all the existing studies were carried out on adults subjects taking less than 5 drugs, and thus cannot be defined as taking polypharmacy according to the current consensus threshold29. For example, Rogers and Aronoff showed that the gut microbiota composition of adult patients chronically taking a single drug is significantly different from that of subjects without pharmacological treatments, and that the association of non-steroidal antinflammatory drugs (NSAIDs) with PPIs influences the gut microbiota in a different way than treatment with NSAIDs alone27. Imhann and colleagues recently demonstrated that, in adult subjects, PPIs, antibiotics, antidepressants and statins are the drug classes with the strongest influence on microbiome composition28. Consistently with our results, few studies carried out in adult subjects without multimorbidity have underlined that PPIs30, 31, antidepressants32, and antipsychotics33, 34 are the main drug classes able to induce modifications of gut microbiota composition alone.

The mechanisms of drug-induced alterations in gut microbiota are only partly known. PPIs can promote the overgrowth of specific taxa by raising luminal pH35, which, in turn, makes enteric mucosa more susceptible to drug-induced damage36. Mucosal modifications of permeability and functionality promoted by drugs can also contribute to select specific microbial taxa. For example, metformin treatment can stimulate goblet cells number and functionality, and thus contribute to select bacteria, such as Akkermansia spp, with a particular trophism towards mucin glycans37. Some drugs may also exhibit bacteriostatic or bactericidal side effects, that can selectively inhibit some bacteria and promote the overexpression of competitors. For example, metformin treatment is associated with overexpression of SCFA producers and Enterobacteriaceae through this mechanism38. Finally, some drugs can trigger local mucosal inflammation by raising its susceptibility to lipopolysaccharide effects, and thus contribute to select specific bacterial populations39.

Moreover, when a large number of drugs are co-administered in the same patient, those gut microbial taxa carrying metabolic functions that can metabolize xenobiotics may have a competitive advantage over other taxa40, 41. These modifications may have both positive and negative implications for the host42.

From the one side, they can contribute to detoxify harmful drug metabolites. On the other side, they can limit drug bioavailability and further contribute to select pathogenic taxa by modifying intestinal microenvironment39. Drugs that are significantly metabolized by gut bacteria include corticosteroids and statins39.

In our study, polypharmacy was significantly associated with the relative abundance of Helicobacter, which has been recently linked to the pathophysiology of a broad spectrum of extragastric diseases43. Similarly, the inverse association of polypharmacy with the relative abundance of members of Lachnospiraceae and Succinivibrionaceae families, producing short-chain fatty acids like butyrate, may have detrimental systemic consequences, since this microbial mediator is positively associated with cardio-respiratory fitness, colonic function, insulin-sensitivity and modulation of inflammation12, 44, 45.

The findings highlighted in Table 3 may be in some cases difficult to interpret, due to the poor knowledge of the microbiological and metabolic characteristics of some detected taxa. However, the current existing literature allows to make some hypothesis. For example, the positive correlation between polypharmacy and Coprobacter relative abundance could be explained by the presence of fermentable polysaccharides, which are among its metabolic substrates, as excipients in drug formulations46. Similarly, the positive association between number of drugs and Prevotella abundance could reflect both specific treatments and disease-related changes in lifestyle47, 48.

The association between polypharmacy and gut microbiota dysbiosis may have detrimental consequences for patients. This concept is supported by the increased mortality at follow-up detected in those patients who had the lowest microbiome biodiversity. Epidemiologic data have recently linked dysbiosis with increased susceptibility to systemic infections, probably as a consequence of altered mucosal permeability in the gut24. Drug-induced dysbiosis has been also identified as a significant predictor of hospitalization in patients with cirrhosis, by increasing the risk of hepatic encephalopathy49, 50. However, in our study a low Chao1 index was not associated with the risk of incident sepsis or rehospitalization. Thus, dysbiosis should be only considered a marker of poor health status, and the effects of gut microbiota composition on clinical outcomes should be better clarified in larger, population-based studies.

Surprisingly, in the present study, the gut microbiota composition of participants showed poor associations with multimorbidity and frailty. This finding is apparently inconsistent with the literature8, 13 and may be explained by the elevated burden of comorbidities and disability exhibited by participants. These features may in some way promote a reduced resilience or “instability” of fecal microbiota, and make it more sensitive to complex drug treatments. Thus, it can be argued that the influence of polypharmacy on gut microbiome composition is in some way mediated by multimorbidity and frailty/disability.

In this context, further studies are needed to verify the hypothesis that frailty and multimorbidity are associated with alterations in gut microbiota composition. However, the relative abundance of some taxa was significantly associated with RCFS or with CIRS Comorbidity Score. For instance, a positive association between unclassified members of Clostridia class and CIRS Comorbidity Score was demonstrated. This is in line with our previous research, showing that multimorbidity is an independent risk factor for the onset of Clostridium difficile colitis or other opportunistic infections51, 52.

Conclusions

In older hospitalized patients, polypharmacy, but not multimorbidity and frailty, was significantly associated with gut microbiota dysbiosis, detected by metagenomics techniques. The severity of dysbiosis was able to significantly predict death after a 2-year follow-up. Future observational and intervention studies should better define the association between geriatric domains and gut microbiota composition, and address the complex relationship between gut microbiota and the physiopathology of aging. The effect of single drug classes on gut bacteria in elderly patients should be also better investigated in the future.

Additional Information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Vaiserman, A. M., Koliada, A. K. & Marotta, F. Gut microbiota: a player in aging and a target for anti-aging intervention. Ageing Res Rev. 35, 36–45 (2017).

  2. 2.

    Salazar, N., Valdes-Varela, L., Gonzalez, S., Gueimonde, M. & de los Reyes-Gavilan, C. G. Nutrition and the gut microbiome in the elderly. Gut Microbes. doi:10.1080/19490976.2016.1256525 (2016).

  3. 3.

    Claesson, M. J. et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 488, 178–184 (2012).

  4. 4.

    O’Toole, P. W. & Jeffery, I. B. Gut microbiota and aging. Science. 350, 1214–1215 (2015).

  5. 5.

    Odamaki, T. et al. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. BMC Microbiol. 16, 90 (2016).

  6. 6.

    Biagi, E. et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One. 5, e10667 (2010).

  7. 7.

    Biagi, E. et al. Gut microbiota and extreme longevity. Curr Biol. 26, 1480–1485 (2016).

  8. 8.

    Jeffery, I. B., Lynch, D. B. & O’Toole, P. W. Composition and temporal stability of gut microbiota in older persons. ISME J. 10, 170–182 (2016).

  9. 9.

    Milani, C. et al. The human gut microbiota and its interactive connections to diet. J Hum Nutr Diet. 29, 539–546 (2016).

  10. 10.

    Claesson, M. J. et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA. 108, 4586–4591 (2011).

  11. 11.

    Zhang, D. et al. Neutrophil ageing is regulated by the microbiome. Nature. 525, 528–532 (2015).

  12. 12.

    Sonnenburg, J. L. & Backhed, F. Diet-microbiota interactions as moderators of human metabolism. Nature. 535, 56–64 (2016).

  13. 13.

    Jackson, M. A. et al. Signatures of early frailty in the gut microbiota. Genome Med. 8, 8 (2016).

  14. 14.

    Mello, A. M., Paroni, G., Daragjati, J. & Pilotto, A. Gastrointestinal microbiota and their contribution to healthy aging. Dig Dis. 34, 194–201 (2016).

  15. 15.

    Milani, C. et al. Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study. Sci Rep. 6, 25945 (2016).

  16. 16.

    Meschi, T. et al. A novel organizational model to face the challenge of multimorbid elderly patients in an internal medicine setting: a case study from Parma Hospital, Italy. Intern Emerg Med. 11, 667–676 (2016).

  17. 17.

    Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N Engl J Med. 375, 2369–2379 (2016).

  18. 18.

    Salvi, F. et al. A manual of guidelines to score the cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 56, 1926–1931 (2008).

  19. 19.

    Rockwood, K. et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 173, 489–495 (2005).

  20. 20.

    Milani, C. et al. Assessing the fecal microbiota: an optimized ion torrent 16S rRNA gene-based analysis protocol. PLoS One. 8, e68739 (2013).

  21. 21.

    Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 7, 335–336 (2010).

  22. 22.

    Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 26, 2460–2461 (2010).

  23. 23.

    Quast, C. et al. The SILVA ribosomial RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41, D590–D596 (2013).

  24. 24.

    Prescott, H. C. et al. Hospitalization type and subsequent severe sepsis. Am J Respir Crit Care Med. 192, 581–588 (2015).

  25. 25.

    Zapata, H. J. & Quagliarello, V. J. The microbiota and microbiome in aging: potential implications in health and age-related diseases. J Am Geriatr Soc. 63, 776–781 (2015).

  26. 26.

    Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 352(6285), 565–569 (2016).

  27. 27.

    Rogers, M. A. M. & Aronoff, D. M. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 22, 178.e1–178.e9 (2016).

  28. 28.

    Imhann, F. et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes.. doi:10.1080/19490976.2017.1284732 (2017).

  29. 29.

    Gnjidic, D. et al. Polypharmacy cut-off and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 65, 989–995 (2012).

  30. 30.

    Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 65, 749–756 (2016).

  31. 31.

    Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut. 65, 740–748 (2016).

  32. 32.

    Macedo, D. et al. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. J Affect Dis. 208, 22–32 (2017).

  33. 33.

    Bahr, S. M. et al. Use of second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 5, e652 (2015).

  34. 34.

    Morgan, A. P. et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS One. 9, e115225 (2014).

  35. 35.

    Freedberg, D. E. et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 149, 883–885 (2015).

  36. 36.

    Wallace, J. L. et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 141, 1314–1322 (2011).

  37. 37.

    Shin, N. R. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 63, 727–735 (2014).

  38. 38.

    Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 528, 262–266 (2015).

  39. 39.

    Weiss, G. A. & Hennet, T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci. 74, 2959–2977 (2017).

  40. 40.

    Maurice, C. F., Haiser, H. J. & Turnbaugh, P. J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell. 152, 39–50 (2013).

  41. 41.

    Nichols, R. G., Hume, N. E., Smith, P. B., Peters, J. M. & Patterson, A. D. Omics approaches to probe microbiota and drug metabolism interactions. Clin Res Toxicol. 29, 1987–1997 (2016).

  42. 42.

    Swanson, H. I. Drug metabolism by the host and gut microbiota: a partnership or rivalry? Drug Metab Dispos. 43, 1499–1504 (2015).

  43. 43.

    Goni, E. & Franceschi, F. Helicobacter pylori and extragastric diseases. Helicobacter. 21, 45–48 (2016).

  44. 44.

    Estaki, M. et al. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomics functions. Microbiome. 4, 42 (2016).

  45. 45.

    Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 500, 541–546 (2013).

  46. 46.

    Nakata, T. et al. Inhibitory effects of laminaran and alginate on production of putrefactive compounds from soy protein by intestinal microbiota in vitro and in rats. Carbohydr Polym. 143, 61–69 (2016).

  47. 47.

    Paroni Sterbini, F. et al. Effects of proton pump inhibitors on the gastric mucosa-associated microbiota in dyspeptic patients. Appl Environ Microbiol. 82, 6633–6644 (2016).

  48. 48.

    Gorvitovskaia, A., Holmes, S. P. & Huse, S. M. Interpreting Prevotella and Bacteroides as biomarkers of diet and lifestyle. Microbiome. 4, 15 (2016).

  49. 49.

    Bajaj, J. S. et al. Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus. Sci Rep. 5, 18559 (2015).

  50. 50.

    Tsai, C. F. et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population-based study. Gastroenterology. 152, 134–141 (2017).

  51. 51.

    Ticinesi, A. et al. Multimorbidity in elderly hospitalised patients and risk of Clostridium difficile infection: a retrospective study with the Cumulative Illness Rating Scale (CIRS). BMJ Open. 5, e009316 (2010).

  52. 52.

    Nouvenne, A. et al. Comorbidities and disease severity as risk factors for carbapenem-resistant Klebsiella pneumoniae colonization: report of an experience in an internal medicine unit. PLoS One. 9, e110001 (2014).

Download references

Acknowledgements

The authors wish to thank GenProbio s.r.l. for financial support of the Laboratory of Probiogenomics. The authors also thank Drs Nicoletta Cerundolo and Alessandra Bologna for the assistance in patient enrolment, and Dr. Elisa Lasala for assistance in data management. The study was fully funded by internal academic funds. No external sponsors had any role in the design, enrolment of patients, data collection, laboratory analyses and interpretation of results.

Author information

Author notes

  1. Andrea Ticinesi and Christian Milani contributed equally to this work.

Affiliations

  1. Department of Medicine and Surgery, University of Parma, Parma, Italy

    • Andrea Ticinesi
    • , Fulvio Lauretani
    • , Antonio Nouvenne
    • , Marcello Maggio
    •  & Tiziana Meschi
  2. Dipartimento Medico-Geriatrico-Riabilitativo, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

    • Andrea Ticinesi
    • , Fulvio Lauretani
    • , Antonio Nouvenne
    • , Marcello Maggio
    •  & Tiziana Meschi
  3. Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy

    • Christian Milani
    • , Leonardo Mancabelli
    • , Gabriele Andrea Lugli
    • , Francesca Turroni
    • , Sabrina Duranti
    • , Marta Mangifesta
    • , Chiara Ferrario
    •  & Marco Ventura
  4. GenProbio S.r.l., Parma, Italy

    • Alice Viappiani

Authors

  1. Search for Andrea Ticinesi in:

  2. Search for Christian Milani in:

  3. Search for Fulvio Lauretani in:

  4. Search for Antonio Nouvenne in:

  5. Search for Leonardo Mancabelli in:

  6. Search for Gabriele Andrea Lugli in:

  7. Search for Francesca Turroni in:

  8. Search for Sabrina Duranti in:

  9. Search for Marta Mangifesta in:

  10. Search for Alice Viappiani in:

  11. Search for Chiara Ferrario in:

  12. Search for Marcello Maggio in:

  13. Search for Marco Ventura in:

  14. Search for Tiziana Meschi in:

Contributions

A.T. conceived the study, collected clinical data, analyzed and interpreted data and wrote the manuscript. C.M. conceived the study, collected laboratory data, analyzed data and wrote the manuscript. F.L. performed statistical analysis and reviewed the manuscript for important intellectual content. A.N. collected clinical data. L.M., G.A.L., F.T., S.D., M.Man., A.V. and C.F. collected laboratory data. M.Mag. reviewed the manuscript for important intellectual content. M.V. and T.M. conceived the study, interpreted data and wrote the manuscript.

Competing Interests

The authors declare that they have no competing interests.

Corresponding author

Correspondence to Andrea Ticinesi.

Electronic supplementary material

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Creative Commons BY

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.